There is a major role for telehealth in oncology care, not only for its convenience but also for giving clinicians the ability to scale nononcologic visits, explained Emeline Aviki, MD, MBA, FACOG, assistant attending gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and lead of the MSKCC Affordability Working Group.
In an interview at our September Institute for Value-Based Medicine® event in New York City, Emeline Aviki, MD, MBA, FACOG, assistant attending gynecologic cancer surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and lead of the MSKCC Affordability Working Group, discussed how benefits of telehealth in oncologic care extend to other specialty care for patients.
Transcript
What role does telehealth play in oncology care?
Telehealth has a major role in cancer care. I think the COVID-19 pandemic showed us how valuable telehealth can be, not only for patient convenience, but also to make sure that patients are compliant with follow-up. Telehealth can offer a lot of convenience for patients.
If you have a follow-up visit with a patient where they don't need a physical exam and they can get their labs at a time that's convenient for them, that's the perfect opportunity to not force them to have to pay for parking [and] take a day off work. Just take a break during work, do your visit with your oncologist, and get back to life.
In addition to offering patients convenient oncology visits, it also offers the ability to scale nononcologic visits that are very helpful for patients; for example, psychiatric care, supportive care for pain management. It would allow you to get those services that are really in shortage to patients no matter where they are.
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Health Equity & Access Weekly Roundup: January 11, 2025
January 11th 2025ACA enrollment rate hits a milestone, though IRA subsidies may not extend beyond 2025; network adequacy standards fail to translate into efficient access to mental health care for Medicaid enrollees; research examines racial disparities in postpartum hypertension and vaccine uptake.
Read More